Medicines
Boldly reshaping the future of cancer care
We are developing novel oncolytic immunotherapies designed to address a broad range of cancer indications.
TUDRIQEV (vusolimogene oderparepvec-wtpg)
Bringing new hope to patients with advanced melanoma
Patient Support
ReplimuneConnect Plus can help patients start and stay on treatment with dedicated support and resources focused on patient care.